- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02134015
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
- Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor Receptor (EGFR) wild-type, locally advance or metastatic NSCLC and have their cancer progressed after at least one prior systemic anti-cancer therapy, available recent or archival tumor specimen and may not have had previous EGFR-targeted regimen, anti-HER2 (Human Epidermal Growth Factor Receptor 2), anti-HER3, or anti-HER4 therapy. Subjects may have high heregulin or low heregulin.
- Part B: Subjects will receive Patritumab or placebo with erlotinib. Overall survival will be the primary outcome. Subjects will need to have EGFR wild-type, locally advance or metastatic NSCLC and have their cancer progressed after at least one prior systemic anti-cancer therapy, available recent or archival tumor specimen and may not have had previous EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy. Only subjects with high heregulin will be enrolled.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Charleroi, Belgium
-
Gent, Belgium, 9000
-
Liege, Belgium
-
Yvoir, Belgium, 5530
-
-
Antwerpen
-
Brasschaat, Antwerpen, Belgium
-
-
Brussels
-
Bruxelles, Brussels, Belgium
-
-
Hainaut
-
Charleroi, Hainaut, Belgium
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada
-
Kingston, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Levis, Quebec, Canada
-
Montreal, Quebec, Canada
-
-
-
-
-
Ostava-Poruba, Czechia
-
Ostrava-Poruba, Czechia
-
-
-
-
-
Gießen, Germany
-
-
Baden-Wurttemberg
-
Esslingen am Neckar, Baden-Wurttemberg, Germany
-
Gerlingen, Baden-Wurttemberg, Germany
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany
-
Ulm, Baden-Württemberg, Germany
-
Villingen-Schwenningen, Baden-Württemberg, Germany
-
-
Bayern
-
Gauting, Bayern, Germany, 82131
-
Muenchen, Bayern, Germany
-
-
Hessen
-
Frankfurt am Main, Hessen, Germany
-
Immenhausen, Hessen, Germany
-
-
Nordrhein-Westfalen
-
Koln, Nordrhein-Westfalen, Germany
-
Rheine, Nordrhein-Westfalen, Germany
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany
-
-
Schleswig-Holstein
-
Grosshansdorf, Schleswig-Holstein, Germany
-
-
-
-
-
Tatabanya, Hungary
-
-
Fejer
-
Szekesfehervar, Fejer, Hungary
-
-
Gyor-Moson-Sopron
-
Gyor, Gyor-Moson-Sopron, Hungary
-
-
Jasz-Nagykun-Szolnok
-
Szolnok, Jasz-Nagykun-Szolnok, Hungary
-
-
-
-
-
Benevento, Italy
-
Bologna, Italy
-
Cremona, Italy
-
Faenza, Italy
-
Genova, Italy
-
Milano, Italy
-
Napoli, Italy
-
Perugia, Italy
-
Ravenna, Italy
-
Rimini, Italy
-
Roma, Italy
-
Rozzano, Italy
-
-
Forli
-
Meldola, Forli, Italy
-
-
Frosinone
-
Sora, Frosinone, Italy
-
-
Lombardia
-
Lecco, Lombardia, Italy
-
-
-
-
-
Krakow, Poland
-
Prabuty, Poland
-
Warszawa, Poland
-
-
Kujawsko-pomorskie
-
Torun, Kujawsko-pomorskie, Poland
-
-
Mazowieckie
-
Otwock, Mazowieckie, Poland
-
-
Pomorskie
-
Gdansk, Pomorskie, Poland
-
-
Zachodniopomorskie
-
Szczecin, Zachodniopomorskie, Poland
-
-
-
-
-
Alicante, Spain
-
Barcelona, Spain
-
Barcelona (2), Spain
-
Barcelona (3), Spain
-
Barcelona (4), Spain
-
Barcelona (5), Spain
-
Barcelona (6), Spain
-
Burgos, Spain
-
Burgos (2), Spain
-
Madrid, Spain
-
Madrid (2), Spain
-
Madrid (3), Spain
-
Madrid (4), Spain
-
Manresa, Spain
-
Manresa (2), Spain
-
Palma de Mallorca, Spain
-
Valencia, Spain
-
Zaragoza, Spain
-
Zaragoza (2), Spain
-
-
A Coruña
-
La Coruna, A Coruña, Spain
-
-
Andalucia
-
Sevilla, Andalucia, Spain
-
-
Valenciana, Comunidad
-
Valencia, Valenciana, Comunidad, Spain
-
-
-
-
-
London, United Kingdom
-
London (2), United Kingdom
-
London (3), United Kingdom
-
Northwood, United Kingdom
-
Rickmansworth, United Kingdom
-
Southampton, United Kingdom
-
Wirral, United Kingdom
-
-
Hertfordshire
-
Stevenage, Hertfordshire, United Kingdom
-
-
-
-
Arizona
-
Glendale, Arizona, United States
-
-
California
-
Duarte, California, United States
-
La Verne, California, United States
-
Los Angeles, California, United States, 43210
-
San Francisco, California, United States
-
-
Florida
-
Port Saint Lucie, Florida, United States
-
Tampa, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
Maywood, Illinois, United States
-
-
Indiana
-
Goshen, Indiana, United States, 46526
-
-
Kentucky
-
Louisville, Kentucky, United States
-
-
Michigan
-
Grand Rapids, Michigan, United States
-
-
Minnesota
-
Saint Cloud, Minnesota, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
Ohio
-
Columbus, Ohio, United States
-
-
Oregon
-
Bend, Oregon, United States
-
Portland, Oregon, United States
-
Redmond, Oregon, United States, 97756
-
-
Tennessee
-
Chattanooga, Tennessee, United States
-
Knoxville, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Dallas, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Virginia
-
Arlington, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be greater or equal to 20 years of age
Must have cytologically or histologically confirmed NSCLC with either:
- Metastatic disease (Stage IV) OR
- Stage IIIB disease not amenable to surgery or curative intent.
Note: It is permissible to use either AJCC Version 6.0 or the AJCC Version 7.0 staging system. For sites that use AJCC Version 7.0, T4M0 patients with other ipsilateral nodules and N0-N2 are still eligible.
- If tumor histology is adenocarcinoma, must have wild-type EGFR genotype as assessed by a validated assay that includes exon 19 deletion and exon 21 (L858R) substitution.
- Must have received one or two prior lines of systemic chemotherapy for advanced or metastatic disease, one of which must be a platinum-doublet therapy.
- Must have disease progression or recurrence documented by radiographic assessment following treatment after last chemotherapy or chemoradiation regimen (completed within the previous 12 months).
- Must have available recent (before treatment start) or archival tumor specimen.
- Must have measurable disease for Part A, measurable disease or non-measurable disease for Part B
- Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Must have adequate hematological function
- Must have adequate renal function
- Must have adequate hepatic function
- Agreement to use effective contraception while on treatment and for at least 6 months after end of treatment
- Must have provided informed consent for study participation.
Exclusion Criteria:
- Lung adenocarcinoma with an Anaplastic Lymphoma Kinase (ALK) gene rearrangement
- Left ventricular ejection fraction (LVEF) less than 45%
- Prior EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy
- History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for greater or equal to 5 years
- History of corneal disease
- History of interstitial lung disease (ILD)
- Clinically active brain metastases
- Uncontrolled hypertension
- Clinically significant ECG changes
- Clinically significant (in the opinion of the Investigator) ascites or pleural effusion requiring chronic medical intervention
- Myocardial infarction within 1 year before enrollment, symptomatic congestive heart failure, unstable angina, or unstable cardiac arrhythmia requiring medication
- Treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 4 weeks before study drug treatment
- Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment; or palliative radiation within 2 weeks before study drug treatment
- Participation in clinical drug trials within 4 weeks
- Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.
- History of hypersensitivity to any of the study drugs or to any excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Placebo + erlotinib
Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
|
Oral erlotinib 150 mg/day
Placebo infusion every 3 weeks
Other Names:
|
EXPERIMENTAL: Patritumab + erlotinib
Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
|
Oral erlotinib 150 mg/day
Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Progression Free Survival (PFS) in Heregulin-high Participants
Time Frame: by trial termination (at 20 months)
|
PFS is defined as the time from the date of randomization to the earlier of the dates of first objective documentation of radiographic disease progression (as per RECIST Version 1.1 per investigator assessment) or death resulting from any cause. Kaplan-Meier Estimate. Confidence interval (CI) for median was computed using the Brookmeyer-Crowley method. 80% confidence interval is included in the data table. |
by trial termination (at 20 months)
|
Part A: Progression Free Survival (PFS) in Heregulin-low Participants
Time Frame: by trial termination (at 20 months)
|
PFS is defined as the time from the date of randomization to the earlier of the dates of first objective documentation of radiographic disease progression (as per RECIST Version 1.1 per investigator assessment) or death resulting from any cause. Kaplan-Meier Estimate. Confidence interval (CI) for median was computed using the Brookmeyer-Crowley method. 80% confidence interval is included in the data table. |
by trial termination (at 20 months)
|
Part B: Overall Survival
Time Frame: 4 years
|
Percentage of participants still alive at the end of Part B
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Overall Survival in HRG High Participants
Time Frame: by trial termination (at 20 months)
|
Key secondary efficacy endpoint: Percentage of participants who survived for the length of the trial
|
by trial termination (at 20 months)
|
Part A: Key Secondary Efficacy Endpoint: Overall Survival in HRG Low Participants
Time Frame: by trial termination (at 20 months)
|
Key secondary efficacy endpoint: Percentage of participants who survived for the length of the trial
|
by trial termination (at 20 months)
|
Part B: Key Secondary Efficacy Endpoint: PFS, TTD
Time Frame: 4 years
|
PFS is defined as the time from the date of randomization to the earlier of the dates of first objective documentation of radiographic disease progression (TTD, as per RECIST Version 1.1 per investigator assessment) or death resulting from any cause.
|
4 years
|
Part A: Objective Response Rate (ORR) in HRG High Participants
Time Frame: by trial termination (at 20 months)
|
Key secondary efficacy endpoint: Objective response is defined as percentage of participants achieving complete response (CR) or partial response (PR) Denominator for percentages is the number of subjects with measurable disease in the full analysis set. The best overall response is the best response [in the order of CR, PR, stable disease (SD), and progressive disease (PD)] among all overall responses recorded from the start of treatment until the subject withdraws from the study. If there is no post-baseline tumor assessment or all post-baseline tumor assessments with overall response being Inevaluable captured in the CRF, the best overall response is classified as Inevaluable. |
by trial termination (at 20 months)
|
Part A: Objective Response Rate (ORR) in HRG Low Participants
Time Frame: by trial termination (at 20 months)
|
Key secondary efficacy endpoint: Objective response is defined as percentage of participants achieving complete response or partial response Denominator for percentages is the number of subjects with measurable disease in the full analysis set. The best overall response is the best response (in the order of CR, PR, SD, and PD) among all overall responses recorded from the start of treatment until the subject withdraws from the study. If there is no post-baseline tumor assessment or all post-baseline tumor assessments with overall response being Inevaluable captured in the CRF, the best overall response is classified as Inevaluable. |
by trial termination (at 20 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
Other Study ID Numbers
- U31287-A-U301
- 2013-004371-12 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California and other collaboratorsCompleted
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
Kyowa Kirin Co., Ltd.TerminatedNon-small-cell Lung CancerJapan
-
Merck Sharp & Dohme LLCCompleted
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
Grupo de Investigación Clínica en Oncología RadioterapiaCompletedSquamous Cell Carcinoma of the Head and NeckSpain
-
New Mexico Cancer Care AllianceCompletedAdvanced Solid Tumor MalignanciesUnited States